Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 4/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931172 | 0.99 | ALDH1A1 (0.45) | MAP3K5CSNK2BHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11931181 | 0.87 | HDAC1 (0.40) | MAP3K5HDAC1ALDH1A1TYK2ROCK2 | |
| SCHEMBL11931184 | 0.87 | HDAC1 (0.40) | MAP3K5HDAC1ALDH1A1TYK2ROCK2 | |
| SCHEMBL14395351 | 0.85 | HDAC1 (0.46) | MAP3K5HDAC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11935123 | 0.85 | HTT (0.45) | MAP3K5HDAC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11931154 | 0.85 | NPC1 (0.43) | MAP3K5HDAC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11931179 | 0.83 | HDAC1 (0.38) | MAP3K5HDAC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11931153 | 0.83 | ADORA3 (0.50) | HDAC1ALDH1A1CDK2GSK3B | |
| SCHEMBL14542651 | 0.83 | MAP3K5 (0.41) | MAP3K5HDAC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11931150 | 0.83 | ADORA3 (0.52) | MAP3K5HDAC1ALDH1A1SMN1; SMN2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7511049-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511049-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7309705-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309705-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| EP-1534710-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CDKN1A | MAP3K5 76/4885CSNK2B 199/4885HDAC1 726/4885 |
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | MAP3K5 11/4885CSNK2B 433/4885HDAC1 1150/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | MAP3K5 11/4885CSNK2B 433/4885HDAC1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.